 A RANDOMIZED TWO ARM PHASE II TRIAL OF PEMBROLIZUMAB ALONE OR SEQUENTIALLY FOLLOWING SINGLE FRACTION NON-ABLATIVE RADIATION TO ONE OF THE TARGET LESIONS, IN PREVIOUSLY TREATED PATIENTS WITH STAGE IV NSCLC: 